PF-152 is a potent, highly selective and orally bioavailable MMP13 inhibitor with Ki of 1.5 nM, with no activity against MMP3 (Ki>10 uM).

Oridonin (Cmpd-5, NSC 250682) is a natural ent-kaurane diterpenoid from Rabdosia rubescens identified as a first-in-class small-molecule inhibitor that directly binds β-arrestin1 and β-arrestin2 with high nanomolar to low micromolar affinity. Oridonin broadly suppresses β-arrestin recruitment, receptor desensitization, internalization, and downstream ERK signaling across multiple GPCR families, and abrogates T-cell chemotaxis.

14:0 PEG2000 PE (DMPE-PEG2000) is a PEG-phospholipid conjugate to prepare nanostructured lipid carrier.

Cephalofurimazine (CFz) is a NanoLuc substrate optimized for enhanced brain performance. When paired with Antares luciferase, it generates over 20 times more signal from the brain compared to the traditional combination of D-luciferin and firefly luciferase.

A methoxy-terminated PEG1000 functionalized with 1,2-dimyristoleoyl-sn-glycerol via an ether linkage. This compound may be used in the formulation of lipid nanoparticles (LNP's) for delivery applications. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.

GLPG3667 is an oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor. It is being developed to treat inflammatory and auto-immune diseases. Biochemical assays showed that GLPG3667 displayed nanomolar potency on TYK2 with a selectivity over other JAK kinases >3-fold. In human PBMC, GLPG3667 showed comparable potency on the IFNα and IL-23 pathways (around 50 nM). Selectivity for TYK2 on the IFNα pathway was >14-fold and >19-fold toward the IL-2 and GM-CSF pathways in human PBMC and whole blood, respectively. Dermal ear inflammation in a mouse model of psoriasis driven by IL-23 was prevented by GLPG3667 with a minimal effective dose of 3 mg/kg given orally once daily. This effect was associated with a decrease in neutrophil infiltration and STAT3 phosphorylation at sites of inflammation. In healthy HV, GLPG3667 completely inhibited IFNα-induced STAT1 and STAT3 phosphorylation but did not impact IL-2- and GM-CSF-induced STAT5 phosphorylation.

mono-Boc-Br MK-6240 Precursor is the precusor of MK-6240.. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .

Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR)

​​GB1107​​ is a novel small-molecule inhibitor specifically designed to target galectin-3 (Gal-3), demonstrating high binding affinity and oral bioavailability.

HOIPIN-1 (JTP-0819958, HOIP inhibitor-1) is a chemical inhibitor of linear ubiquitin chain assembly complex (LUBAC, IC50=2.8 uM), specifically generates Met1-linked linear ubiquitin chains through the ubiquitin ligase activity in HOIP, and activates the N

ARV471 is an orally bioavailable estrogen receptor-targeting (ER-targeting) PROTAC for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

UHMCP1 is a small molecule that prevents the SF3b155/U2AF65 interaction, binds to the hydrophobic pocket of the U2AF65 UHM domain (Kd=1-20 uM), impacts splicing and cell viability.

Ac-ATAD-AFC(Caspase-12 Substrate) is a fluorogenic substrate for caspase-12.

DesMEM AZD4694（AZD4694 Precursor 1）is the precursor of [18F] AZD4694 for the synthesis of [18F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques.

Acid-degradable PEG Lipid (ADP) composed of polyethylene glycol lipid is synthesized with the azido-acetal linker and used to generate RD-LNPs, which significantly improves the performance of LNP-mRNA complexes in vitro and in vivo.

This product is a ready-to-use colorimetric substrate for Caspases that recognize the amino acid sequence AEVD. Caspase activity can be quantified by spectrophotometric detection of free pNA (l = 400 nm) after cleaved from the peptide substrate AEVD-pNA, using a spectrophotometer or multi-well plate reader.

The Precursor of NOP-1A.  (11)C-NOP-1A is a useful radioligand for quantifying NOP receptors in the monkey brain, and its radiation dose is similar to that of other (11)C-labeled ligands for neuroreceptors.

NOP-1A standard. 11C-NOP-1A is a new radioligand for thenociceptin/orphanin FQ peptide (NOP) receptor, with high affinity (Ki, 0.15 nM) and appropriate lipophilicity (measured logD, 3.4) for PET brain imaging. 11C-NOP-1A is the the first successful radioligand to image NOP receptors in rat and monkey brain. 11C-NOP-1A is a selective antagonist at the NOP receptor and has high affinity and appropriate lipophilicity for blood–brain barrier permeability. 11C-NOP-1A imaging in rhesus monkeys showed high brain uptake and a large receptor-specific signal and could be quantified with the gold standard method of compartmental modeling. In humans 1C-NOP-1A reliably quantified NOP receptors in human brain both in large brain regions and at a voxelwise level using parametric imaging. The radiation absorbed dose in humans was similar to that observed with other 11C-labeled ligands and would allow multiple scans of a single subject. Thus, 11C-NOP-1A is a promising radioligand for reliably quantifying NOP receptors in human brain.

JC19 is a a cysteine-reactive small molecule degrader of SARS-CoV-2 nsp14 with DC50 of 8.7 uM in HEK293T cells.

ZSH-2208 is a synthetic analog of all-trans retinoic acid (ATRA) designed to overcome resistance and improve differentiation therapy in acute promyelocytic leukemia (APL) and other malignancies. In published studies, ZSH-2208 has shown superior anti-proliferative and pro-differentiation activity compared to ATRA in ATRA-resistant APL cell lines such as NB4-R2. For example, ZSH-2208 induced significant G1 phase arrest and granulocytic differentiation in NB4-R2 cells at concentrations around 1–10 µM, whereas ATRA was largely ineffective at equivalent doses. In mouse xenograft models, ZSH-2208 treatment led to marked tumor growth inhibition without the rapid metabolic degradation seen with ATRA. These data suggest that ZSH-2208 is a promising candidate for treating retinoic acid-resistant leukemias and potentially other cancers sensitive to retinoid signaling.

SH514 is a specific small molecule inhibitor of interferon regulatory factor 4 (IRF4) with IC50 of 2.63 uM, inhibits proliferation of IRF4-high-expressing NCI-H929 and MM.1R MM cells with IC50 of 0.08 uM and 0.11 uM, respectively.

PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.

Targeting the bacterial sliding clamp peptide 46 is a short peptide targeting the bacterial sliding clamp(SC), inhibiting SC-dependent DNA synthesis.

BC18630 free base (BC 18630) is a small molecule inhibitor of the E3 ubiquitin ligase subunit DCAF7, potently inhibits SARS-CoV-2 infection with IC50 of 39 nM in cell-based assays.

BC18630 (BC 18630) is a small molecule inhibitor of the E3 ubiquitin ligase subunit DCAF7, potently inhibits SARS-CoV-2 infection with IC50 of 39 nM in cell-based assays.

DP308 is a novel and effective 53BP1 tandem Tudor domain (TTD) inhibitor, disrupts the binding between 53BP1 and H4K20me2 peptide with IC50 of 1.69 uM.

AC-003 is a novel, orally administered small-molecule inhibitor targeting receptor-interacting protein kinase 1 (RIPK1), demonstrating therapeutic potential for the treatment of idiopathic pulmonary fibrosis (IPF).

AC3573 (AC-3573) is a potent, specific small molecule inhibitor of HER3.AC3573 abrogates HER2–HER3 signalling in cells and is more specific for HER3, inhibits NRG (heregulin)-induced HER3 phosphorylation with IC50 of 10 uM, abrogates the formation of the active HER2-HER3 heterodimer, inhibits oncogenic downstream signalling in SK-BR-3 breast cancer cells.

F1957-0088 is a small molecule targeting the UHRF1 tandem Tudor domain (TTD) with TR-FRET (TTD vs. H3K9me3) EC50 of 45.1 uM.

DMG-PEG-Mannose is a specialized functionalized lipid used primarily for the targeted delivery of lipid nanoparticles (LNPs) and liposomes to cells expressing mannose receptors, such as macrophages and dendritic cells. It combines a 1,2-dimyristoyl-sn-glycerol (DMG) lipid anchor with a polyethylene glycol (PEG) spacer and a terminal mannose sugar moiety.